乳腺癌患者血浆循环DNA中Sox17基因甲基化检测的临床意义

符德元; 任传利; 谭好升; 魏金丽; 祝玉祥; 何春兰; 邵稳喜; 章佳新

doi:10.3969/j.issn.1007-3969.2014.11.002

您当前的位置：

首页 >

文章列表页 >

乳腺癌患者血浆循环DNA中Sox17基因甲基化检测的临床意义

更新时间：2025-12-31

- 乳腺癌患者血浆循环DNA中Sox17基因甲基化检测的临床意义
- Clinical significance of Sox17 gene promoter methylation in plasma circulating DNA in breast cancer patients
- 中国癌症杂志 2014年24卷第11期页码：808-813
- 作者机构：
  
  江苏省苏北人民医院甲状腺乳腺外科,江苏,扬州
- 作者简介：
- 基金信息：
  
  国家自然科学基金资助项目
- DOI：10.3969/j.issn.1007-3969.2014.11.002
  中图分类号：
- 网络出版：2015-05-05，
  
  纸质出版：2014-05-05
- 稿件说明：
移动端阅览
符德元,任传利,谭好升,魏金丽,祝玉祥,何春兰,邵稳喜,章佳新. 乳腺癌患者血浆循环DNA中Sox17基因甲基化检测的临床意义[J]. 中国癌症杂志, 2014, 24(11): 808-813.

符德元, 任传利, 谭好升, et al. Clinical significance of Sox17 gene promoter methylation in plasma circulating DNA in breast cancer patients[J]. China Oncology, 2014, 24(11): 808-813.
符德元,任传利,谭好升,魏金丽,祝玉祥,何春兰,邵稳喜,章佳新. 乳腺癌患者血浆循环DNA中Sox17基因甲基化检测的临床意义[J]. 中国癌症杂志, 2014, 24(11): 808-813. DOI： 10.3969/j.issn.1007-3969.2014.11.002.

符德元, 任传利, 谭好升, et al. Clinical significance of Sox17 gene promoter methylation in plasma circulating DNA in breast cancer patients[J]. China Oncology, 2014, 24(11): 808-813. DOI： 10.3969/j.issn.1007-3969.2014.11.002.

摘要

背景与目的：在乳腺癌发生、发展过程中，甲基化异常是导致抑癌基因失活的重要机制，是一种可用于肿瘤诊断及预后判断、有价值的生物标志物。本研究旨在通过检测乳腺癌组织及其相应的血浆循环DNA中Sox17基因的甲基化状况，探讨其在乳腺癌早期诊断和预后判断方面的应用价值。方法：采用甲基化特异性聚合酶链反应(methylation specific-PCR，MSP)法，对86例乳腺癌组织、36例乳腺良性肿瘤的癌旁正常组织及其配对的血浆循环DNA中Sox17基因启动子甲基化进行检测，并结合乳腺癌的主要临床病理特性进行分析。结果：86例乳腺癌组织中Sox17基因启动子的甲基化率为77.9%(67/86)，与其相应血浆循环DNA中Sox17基因启动子的甲基化率为61.6%(53/86)，36例癌旁正常乳腺组织及血浆中均未检测到Sox17基因异常甲基化。患者血浆循环DNA中Sox17基因启动子的甲基化与肿瘤组织中该基因的甲基化显著相关(r=0.502，P=0.000)。在乳腺癌组织标本中Sox17基因甲基化率与患者肿瘤分期(χ2=6.18，P=0.041)、淋巴结转移(χ2=13.54，P=0.001)显著相关，在血浆标本中，Sox17基因甲基化率与患者肿瘤分期(χ2=27.06，P=0.000)、肿瘤大小(χ2=9.65，P=0.007)及淋巴结转移(χ2=20.80，P=0.000)显著相关，与患者年龄、组织学分级及ER、PR、HER-2/neu等指标差异无统计学意义(P0.05)。结论：Sox17基因启动子甲基化在乳腺癌的发生、发展中起着重要作用，可能与乳腺癌的预后相关。血浆中Sox17基因甲基化，是一个有潜在应用价值的生物标志物。

Abstract

Background and purpose: Aberrant DNA methylation that leads to the inactivation of tumor suppressor genes plays important roles in development and progression of breast cancer. Clinically

related gene methylation is considered to be a promising biomarker for tumor diagnosis and prognosis. This study aimed to investigate the methylation status of Sox17 gene in breast cancer tissue and its corresponding plasma circulating DNA

as well as to investigate its value in breast cancer early diagnosis and prognosis. Methods: The Sox17 gene promoter methylation status was detected by MSP in 86 cases of breast cancer

36 normal breast tissues and its paired plasma DNA

the results were analyzed with corresponding clinical and pathological features. Results: The frequency of Sox17 gene methylation rate among 86 breast cancer tissues was 77.9%(67/86)

and was 61.6%(53/86)in plasma circulating DNA

however

no Sox17 gene methylation was found in normal breast tissues. Sox17 gene promoter methylation in plasma circulating DNA was significantly associated with the methylation status in tumor tissues (r=0.502

P=0.000). In breast cancer tissue specimens

Sox17 methylation status was significantly correlated with tumor stage (χ2=6.18

P=0.041) and lymph node metastasis (χ2=13.54

P=0.001); Sox17 gene methylation rate was significantly correlated with tumor stage (χ2=27.06

P=0.000)

tumor size (χ2=9.65

P=0.007) and lymph node metastasis (χ2=20.80

P=0.000) in plasma samples

and there was no significant difference of Sox17 gene methylation between patient age

histological grade and ER

HER-2/neu status. Conclusion: Sox17 gene promoter methylation plays an important role in the carcinogenesis and development of breast cancer

and may be associated with the prognosis of breast cancer. Furthermore

methylated Sox17 gene may be a useful tumor biomarker in plasma circulating DNA for breast cancer detection and disease monitoring.

关键词

Keywords

references

浏览量

2413

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

miR-335靶向Rho相关卷曲螺旋形成蛋白激酶1抑制人骨肉瘤细胞MG-63侵袭转移的实验研究

宫颈癌细胞系RASSFIA基因启动子及第1外显子区甲基化状态的研究